Interferome V2.0: an Updated Database of Annotated Interferon-regulated Genes

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2012 Dec 4

PMID 23203888

Citations 525

Authors

Irina Rusinova

Sam Forster

Simon Yu

Anitha Kannan

Marion Masse

Helen Cumming

Ross Chapman

Paul J Hertzog

Affiliations

Soon will be listed here.

Abstract

Interferome v2.0 (http://interferome.its.monash.edu.au/interferome/) is an update of an earlier version of the Interferome DB published in the 2009 NAR database edition. Vastly improved computational infrastructure now enables more complex and faster queries, and supports more data sets from types I, II and III interferon (IFN)-treated cells, mice or humans. Quantitative, MIAME compliant data are collected, subjected to thorough, standardized, quantitative and statistical analyses and then significant changes in gene expression are uploaded. Comprehensive manual collection of metadata in v2.0 allows flexible, detailed search capacity including the parameters: range of -fold change, IFN type, concentration and time, and cell/tissue type. There is no limit to the number of genes that can be used to search the database in a single query. Secondary analysis such as gene ontology, regulatory factors, chromosomal location or tissue expression plots of IFN-regulated genes (IRGs) can be performed in Interferome v2.0, or data can be downloaded in convenient text formats compatible with common secondary analysis programs. Given the importance of IFN to innate immune responses in infectious, inflammatory diseases and cancer, this upgrade of the Interferome to version 2.0 will facilitate the identification of gene signatures of importance in the pathogenesis of these diseases.

Citing Articles

Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection.

Broomfield B, Tan C, Qin R, Abberger H, Duckworth B, Alvarado C J Exp Med. 2025; 222(5).

PMID: 40062995 PMC: 11893171. DOI: 10.1084/jem.20241148.

Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions.

Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M Cell Mol Life Sci. 2025; 82(1):98.

PMID: 40025196 PMC: 11872851. DOI: 10.1007/s00018-025-05625-9.

Integrated transcriptomic profiling reveals a STING-mediated Type II Interferon signature in SOD1-mutant amyotrophic lateral sclerosis models.

Hiew J, Lim Y, Liu H, Ng C Commun Biol. 2025; 8(1):347.

PMID: 40025162 PMC: 11873215. DOI: 10.1038/s42003-025-07790-w.

Protective role of mitophagy on microglia-mediated neuroinflammatory injury through mtDNA-STING signaling in manganese-induced parkinsonism.

Lu Y, Gao L, Yang Y, Shi D, Zhang Z, Wang X J Neuroinflammation. 2025; 22(1):55.

PMID: 40022162 PMC: 11869743. DOI: 10.1186/s12974-025-03396-5.

RBM43 controls PGC1α translation and a PGC1α-STING signaling axis.

Dumesic P, Wilensky S, Bose S, Van Vranken J, Gygi S, Spiegelman B Cell Metab. 2025; 37(3):742-757.e8.

PMID: 39965564 PMC: 11885043. DOI: 10.1016/j.cmet.2025.01.013.

References

Bidwell B, Slaney C, Withana N, Forster S, Cao Y, Loi S . Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18(8):1224-31. DOI: 10.1038/nm.2830. View

de Weerd N, Samarajiwa S, Hertzog P . Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007; 282(28):20053-7. DOI: 10.1074/jbc.R700006200. View

Harman A, Lai J, Turville S, Samarajiwa S, Gray L, Marsden V . HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood. 2011; 118(2):298-308. PMC: 4123420. DOI: 10.1182/blood-2010-07-297721. View

Hertzog P . Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses. Immunol Cell Biol. 2012; 90(5):471-3. DOI: 10.1038/icb.2012.15. View

Ruiz-Riol M, Barnils M, Colobran Oriol R, Sanchez Pla A, Borras Serres F, Lucas-Martin A . Analysis of the cumulative changes in Graves' disease thyroid glands points to IFN signature, plasmacytoid DCs and alternatively activated macrophages as chronicity determining factors. J Autoimmun. 2011; 36(3-4):189-200. DOI: 10.1016/j.jaut.2011.01.002. View

Nagano Y, Kojima Y . [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. C R Seances Soc Biol Fil. 1954; 148(19-20):1700-2. View

Vance R, Isberg R, Portnoy D . Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe. 2009; 6(1):10-21. PMC: 2777727. DOI: 10.1016/j.chom.2009.06.007. View

Isaacs A, Lindenmann J . Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267. J Immunol. 2015; 195(5):1911-20. View

Platanias L . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5(5):375-86. DOI: 10.1038/nri1604. View

10.

Pan W . A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. Bioinformatics. 2002; 18(4):546-54. DOI: 10.1093/bioinformatics/18.4.546. View

11.

Muller U, Steinhoff U, Reis L, Hemmi S, Pavlovic J, Zinkernagel R . Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264(5167):1918-21. DOI: 10.1126/science.8009221. View

12.

Bolstad B, Irizarry R, Astrand M, Speed T . A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19(2):185-93. DOI: 10.1093/bioinformatics/19.2.185. View

13.

Der S, Zhou A, Williams B, Silverman R . Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998; 95(26):15623-8. PMC: 28094. DOI: 10.1073/pnas.95.26.15623. View

14.

Lichtman E, Helfgott S, Kriegel M . Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol. 2012; 143(3):210-21. PMC: 3358492. DOI: 10.1016/j.clim.2012.03.005. View

15.

Lamers M, Kirgiz O, Heidrich B, Wedemeyer H, Drenth J . Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012; 17(6):1029-37. DOI: 10.3851/IMP2306. View

16.

Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S . BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009; 10(11):R130. PMC: 3091323. DOI: 10.1186/gb-2009-10-11-r130. View

17.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View

18.

Takeuchi O, Akira S . Pattern recognition receptors and inflammation. Cell. 2010; 140(6):805-20. DOI: 10.1016/j.cell.2010.01.022. View

19.

Smyth G, Michaud J, Scott H . Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005; 21(9):2067-75. DOI: 10.1093/bioinformatics/bti270. View

20.

Croze E, Yamaguchi K, Knappertz V, Reder A, Salamon H . Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2012; 13(5):443-51. PMC: 3793239. DOI: 10.1038/tpj.2012.27. View